Considering the effect of FXR and TGR5 signaling on glucose and lipid metabolism, it is believable that the molecules which can modulate both receptors (i.e., FXR agonists) or regulate endogenous levels of bile acids might have therapeutic effects on NAFLD/NASH (summarized in Fig. 3). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.